ALIGN PsA: Advancing a Multidisciplinary Approach in PsA
Psoriasis is a chronic skin condition that is associated with several comorbidities and co-manifestations that reduce patient quality of life. Psoriatic arthritis (PsA) is a form of spondyloarthritis that is associated with psoriasis and typically involves peripheral disease, axial disease, enthesitis, dactylitis, and skin and nail lesions. Psoriatic arthritis is associated with a substantial psychosocial and functional burden and can lead to irreversible joint damage if left untreated. Early and accurate diagnosis of PsA is critical. The symptoms of PsA span the fields of dermatology and rheumatology, and professional societies recommend co-management between rheumatologists and dermatologists to optimally treat the condition. Dermatologists must be familiar with the hallmarks of PsA, while rheumatologists should understand the impact that cutaneous manifestations of PsA can have on quality of life. Current models of co-management include combined clinics and virtual clinics, which have had success in case reports. Co-management of PsA has been associated with more use of biologics, better preventive care, and higher patient satisfaction.
Psoriatic arthritis, psoriasis, biologics, interdisciplinary care, comorbidities, immune arthritis
* Clinical Professor of Dermatology, University of Alabama Medical Center Birmingham, AL
** Franchellie M. Cadwell Associate Professor of Medicine, Weill Medical College of Cornell University, The Hospital for Special Surgery, New York Presbyterian Hospital, New York, NY
Psoriatic Disease: Signs, Symptoms, and Diagnosis
Psoriasis is a chronic, inflammatory disease with a probable genetic and environmental etiology. Although psoriasis is often considered a disease of the skin, the condition can have severe musculoskeletal and systemic comorbidities and co-manifestations.4,13 These conditions include Crohn’s disease, uveitis, celiac disease, and metabolic syndrome. Psoriasis has also been associated with psychiatric disorders, such as anxiety and depression.13
Eric W. Baum, MD, MS
Sergio Schwartzman, MD
To claim your CME credit for this activity go to: http://www.focusmeded.com/eval-alignpsa/
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Focus Medical Communications. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Psoriasis is a common skin condition that affects approximately 3.2% of adults in the United States. Psoriasis is associated with a number of coexisting conditions, the most prevalent of which is psoriatic arthritis (PsA). Among people with psoriasis, the prevalence of PsA is estimated to be between 6% and 41%. According to expert KOL opinion, interdisciplinary cooperation between dermatologists and rheumatologists remains a significant practice gap in the management of psoriasis/psoriatic arthritis (PsA). Combined clinics offer a promising care model because they increase collaborative care for patients with complex diseases, enhance professional development, provide unique training opportunities for medical students, residents, and fellows in a setting where they can learn the importance of communication between patients and provider and allow the opportunity to study long-term outcomes and outcome measurements in patients with complex diseases.
- Analyze the roles of the dermatologist and rheumatologist in the treatment of psoriatic disease (PD), including both psoriasis (PsO) and psoriatic arthritis (PsA)
- Discuss how to integrate interdisciplinary collaboration into daily clinical practice
- Define PsA under the spondyloarthritis umbrella and discuss CASPAR criteria
- Describe the detrimental effects and comorbidities of untreated PD
- Discuss comorbidities associated with PD
- Define the patient-centric effects of PD, including aspects that affect quality of life, and recommend techniques to treat the “whole” patient
- Review data on new and emerging therapies for PD
- Demonstrate strategies to incorporate diagnostic and treatment updates into clinical practice and how to tailor treatment to individual cases
Disclosure of Conflicts of Interest
All faculty and staff involved in the planning or presentation of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Charles Willis, Director of Continuing Education, consults for Pfizer, Inc., all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relationships to disclose.
Learner Assurance Statement
The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
Additional Planners/Reviewers Affiliation and Disclosure Statements
Anne Michaels: Planning Committee, has no relationships to disclose.
Emma Patten: Medical Writer, has no relationships to disclose.
Eric W. Baum, MD, MS: Dr. Baum has served on an advisory board for Janssen. He has also been on a speakers’ bureau for Aclaris, Celgene Corporation, Encore, Dermira, Pfizer, PruGen, Novartis, Sanofi-Regeneron, and UCB Inc.
Sergio Schwartzman, MD: Dr. Schwartzman has been a consultant for AbbVie Inc.; Crescendo Bioscience; Genentech, Inc.; Hospira; Janssen Biotech Inc.; Novartis; and Regeneron. He has served on a speakers’ bureau for AbbVie Inc.; Crescendo Bioscience; Janssen Biotech Inc.; Genentech, Inc.; Pfizer; and UCB Inc.
- Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis Prevalence Among Adults in the United States. J Am Acad Dermatol. 2014;70(3):512-516.
- Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545-568.
- Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493-1499.
- Cobo-Ibanez T, Villaverde V, Seoane-Mato D, et al. Multidisciplinary dermatology-rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review. Rheumatol Int. 2016;36(2):221-229.
- Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-970.
- Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045-1050.
- Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242-248.
- Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87-97..
- Jagadeesan S, Shenoy P. Arthropathy in dermatology: a comprehensive review. Indian Dermatol Online J. 2017;8(2):79-93.
- Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis & Rheumatol. 2016;68(5):1060-1071.
- Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008; 58(5):851-864.
- Gratacos-Masmitja J, Luelmo-Aguilar J, Zarco-Montejo P, et al. Points to consider in the foundation of multidisciplinary units for psoriatic arthritis: a Delphi study and a systematic review of the literature. Adv Ther. 2017;33(12):2150-2159.
- Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9-20.
- Gottlieb AB, Kircik L, Eisen D, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatolog Treat. 2006; 17(6):343-352.
- Cauli A, Gladman DD, Mathieu A, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol. 2011;38(5):898-903.
- Orbai AM, de Wit M, Mease PJ, et al. Updating the psoriatic arthritis (PsA) core domain set: a report from the PsA Workshop at OMERACT 2016. J Rheumatol. 2017;44(10):1522-1528.
- Sudol-Szopinska I, Matuszewska G, Kwiatkowska B, Pracon G. Diagnostic imaging of psoriatic arthritis. Part I: etiopathogenesis, classifications and radiographic features. J of Ultrason. 2016;16(64):65-77.
- Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology. 2003;42(12):1460-1468.
- Polachek A, Li S, Chandran V, Gladman DD. Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome. Arthritis Care Res (Hoboken). 2017;69(11):1685-1691.
- Kristensen S, Christensen JH, Schmidt EB, et al. Assessment of enthesitis in patients with psoriatic arthritis using clinical examination and ultrasound. Muscles Ligaments Tendons J. 2016; 6(2):241-247.
- Bagel J, Schwartzman S. Enthesitis and dactylitis in psoriatic disease: a guide for dermatologists. Am J Clin Dermatol. 2018. doi: 10.1007/s40257-018-0377-2.
- Brockbank J, Stein M, Schentag C, Gladman D. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64(2):188-190.
- Gladman DD, Ziouzina O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013;40(8):1357-1359.
- Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61(2):233-239.
- Aydin SZ, Castillo-Gallego C, Ash ZR, et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology. 2012;225(3):231-235.
- Love TJ, Gudjonsson JE, Valdimarsson H, Gudbjornsson B. Psoriatic arthritis and onycholysis—results from the cross-sectional Reykjavik psoriatic arthritis study. J Rheumatol. 2012; 39(7):1441-1444.
- Rouzaud M, Sevrain M, Villani AP, et al. Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. J Eur Acad Dermatol Venereol. 2014;28 (suppl 5):17-26.
- Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-2673.
- Baran R, Sigurgeirsson B. Psoriatic nail disease, a predictor of psoriatic arthritis. Br J Dermatol. 2014;171(5):935-936.
- Bonifati C, Elia F, Francesconi F, et al. The diagnosis of early psoriatic arthritis in an outpatient dermatological centre for psoriasis. J Eur Acad Dermatol Venereol. 2012;26(5):627-633.
- Khraishi M, Landells I, Mugford G. The Self-Administered Psoriasis and Arthritis Screening Questionnaire (PASQ): a sensitive and specific tool for the diagnosis of early and established psoriatic arthritis. Psoriasis Forum. 2010;16(2):9-16.
- Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27(3):469-474.
- Gladman DD, Schentag CT, Tom BD, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis. 2009;68(4):497-501.
- Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57(4):581-587.
- Coates LC, Aslam T, Al Balushi F, et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol. 2013;168(4):802-807.
- Cohen JM, Husni ME, Qureshi AA, Merola JF. Psoriatic arthritis: it’s as easy as PSA. J Am Acad Dermatol. 2015;72(5):905-906.
- Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401-407.
- Feldman SR, Zhao Y, Shi L, Tran MH, Lu J. Economic and comorbidity burden among moderate‐to‐severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken). 2015;67(5):708-717.
- Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. PT. 2010;35(12):680-689.
- Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91-102.
- Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850.
- American College of Rheumatology. Psoriatic Arthritis. https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Psoriatic-Arthritis. Accessed October 8, 2018.
- Davio K. ACR and NPF Unveil new clinical guideline for treating psoriatic arthritis.; https://www.ajmc.com/conferences/acr-2017/acr-and-npf-unveil-new-clinical-guideline-for-treatingpsoriatic-arthritis. Published November 8, 2017. Accessed October 9, 2018.
- Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016;12(12):743-750.
- Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised, controlled trial. Lancet. 2015;386(10012):2489-2498.
- Gossec L, McGonagle D, Korotaeva T, et al. Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature. J. Rheumatol. 2018;45(1):6-13.
- Coates LC, Lubrano E, Perrotta FM, Emery P, Conaghan PG, Helliwell PS. What should be the primary target of “treat to target” in psoriatic arthritis? J Rheumatol. 2018. doi: 10.3899/jrheum.180267.
- Mease P. A short history of biological therapy for psoriatic arthritis. Clin Exp Rheumatol. 2015;33(5 suppl 93):S104-108.
- Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385-390.
- Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264-2272.
- Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150.
- Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebocontrolled trial. Arthritis Rheum. 2005;52(10):3279-3289.
- Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68(5):702-709.
- Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1): 48-55.
- Kavanaugh A, Husni ME, Harrison DD, et al. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study. Arthritis Rheumatol. 2017;69(11):2151-2161.
- Lemos LL, de Oliveira Costa J, Almeida AM, et al. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int. 2014;34(10):1345-1360.
- Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035-1050.
- Bonovas S, Minozzi S, Lytras T, et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(suppl 1):35-54.
- D’Angelo S, Tramontano G, Gilio M, Leccese P, Olivieri I. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for nonresponders. Open Access Rheumatol.: Research and Reviews. 2017; 9:21-28.
- Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology. 2012;51(8):1368-1377.
- Combe B, Goupille P, Kuntz JL, Tebib J, LiotÈ F, Bregeon C. Sulphasalazine inpsoriatic arthritis: a randomized, multicentre, placebo-controlled study. Rheumatology. 1996;35(7):664-668.
- Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39(12):2013-2020.
- Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50(6):1939-1950.
- McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137-1146.
- Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)- controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79.
- Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317-2327.
- Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370(24):2295-2306.
- McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebocontrolled PSUMMIT 1 trial. Lancet. 2013;382(9894):780-789.
- Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000-1006.
- Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990-999.
- Deodhar A, Gottlieb AB, Boehncke W-H, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391(10136):2213-2224.
- Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 mrandomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020.
- Cutolo M, Myerson GE, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43(9):1724-1734.
- Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065-1073.
- Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525-1536.
- Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537-1550.
- US Food & Drug Administration. Biosimilars. September 6, 2018; https://www.fda.gov/Drug/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/. Published September 6, 2018. Accessed October 14, 2018.
- Bridges SL, Jr., White DW, Worthing AB, et al. The science behind biosimilars: entering a new era of biologic therapy. Arthritis Rheum. 2018;70(3):334-344.
- Committee on Rheumatologic Care. American College of Rheumatology position statement, biosimilars. Atlanta, GA: American College of Rheumatology; March, 2018. https://www.rheumatology.org/Portals/0/Files/Biosimilars-Position-Statement.pdf. Accessed November 15, 2018.
- Krendyukov A, Schiestl M. Extrapolation concept at work with biosimilar: a decade of experience in oncology. ESMO open. 2018;3(2):e000319.
- Psoriasis & Psoriatic Arthritis Clinics Multicenter Advancement Network. Clinics. http://www.ppacman.org/clinics.html. Accessed October 12, 2018.
- Beary JF, III. Combined care of the rheumatic patient. JAMA. 1985;254(23):3374-3375.
- Rhematologic Dermatology Society. Our mission. http://www.rheumaderm-society.org/aboutrds/our-mission/. Accessed October 12, 2018.
- Psoriasis & Psoriatic Arthritis Clinics Multicenter Advancement Network. About Us. http://www.ppacman.org/about.html. Accessed October 12, 2018.
- Sasaki JL, Koo JY. Skin therapies: dermatologic perspective on the rheumatology-dermatology interface. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S78-S81.
- Taylor SL, Petrie M, O’Rourke KS, Feldman SR. Rheumatologists’ recommendations on what to do in the dermatology office to evaluate and manage psoriasis patients’ joint symptoms. J Dermatolog Treat. 2009;20(6):350-353.
- Villani AP, Rouzaud M, Sevrain M, et al. Symptoms dermatologists should look for in daily practice to improve detection of psoriatic arthritis in psoriasis patients: an expert group consensus. J Eur Acad Dermatol Venereol. 2014; 28(suppl 5):27-32.
- Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2001;45(2):151-158.
- de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143(2):223-231.
- Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59(7):996-1001.
- Coates LC, Helliwell PS. Psoriasis flare with corticosteroid use in psoriatic arthritis. Br J Dermatol. 2015;174(1):219-221.
- Velez NF, Wei-Passanese EX, Husni ME, Mody EA, Qureshi AA. Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. Arch Dermatol Res. 2012;304(1):7-13.
- Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70(12):2152-2154.
- Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180-1185.
- Curtis JR, Arora T, Narongroeknawin P, et al. The delivery of evidence-based preventive care for older Americans with arthritis. Arthritis Res Ther. 2010;12(4):R144-R144.
- Okhovat JP, Ogdie A, Reddy SM, Rosen CF, Scher JU, Merola JF. Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) survey: benefits and challenges of combined rheumatology-dermatology clinics. J Rheumatol. 2017;44(5):693-694.
- Queiro R, Coto P. Multidisciplinary care for psoriatic disease: Where we are and where we need to go. Rheumatology (Oxford). 2017;56(11):1829-1831.
- Soleymani T, Reddy SM, Cohen JM, Neimann AL. Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients. Curr Rheumatol Rep. 2017;20(1):1.
- Luelmo J, Gratacos J, Moreno Martinez-Losa M, et al. Multidisciplinary psoriasis and psoriatic arthritis unit: report of 4 years’ experience. Actas Dermosifiliogr. 2014;105(4):371-377.
- Urruticoechea-Arana A, Serra Torres M, Hergueta Diaz M, et al. Experience and Satisfaction With a Multidisciplinary Care Unit for Patients With Psoriasis and Psoriatic Arthritis. Reumatol Clin. 2017. doi: 10.1016/j.reuma.2017.07.007.
- Samycia M, McCourt C, Shojania K, Au S. Experiences from a combined dermatology and rheumatology clinic: a retrospective review. J Cutan Med Surg. 2016;20(5):486-489.
- UCB. Bimekizumab demonstrates impressive joint and skin responses for psoriatic arthritis patients. https://www.ucb.com/stories-media/Press-Releases/article/Bimekizumab-demonstratesimpressive-joint-and-skin-responses-for-psoriatic-arthritis-patients-nbsp. Published December 20, 2017. Accessed October 12, 2018.
- Mease PJ, Kellner H, Morita A, et al. OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. Ann Rheum Dis. 2018;77(suppl 2):200.
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (SELECT - PsA 1). https://clinicaltrials.gov/ct2/show/NCT03104400. Accessed October 12, 2018.
- Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis (PATERA). https://clinicaltrials.gov/ct2/show/NCT03598751. Accessed October 12, 2018.
The Guest Editors acknowledge the editorial assistance of Focus Medical Communications, Global Academy for Medical Education and Emma Patten, medical writer, in the development of this supplement. The manuscript was reviewed and approved by the Guest Editors as well as the Editors of Seminars in Cutaneous Medicine and Surgery. The ideas and opinions expressed in this supplement are those of the Guest Editors and do not necessarily reflect the views of the supporter, Focus Medical Communications, Global Academy for Medical Education, and Annenberg Center for Health Sciences and Education, or the publisher.
STATEMENT OF PURPOSE
Seminars in Cutaneous Medicine and Surgery presents well-rounded and authoritative discussions of important clinical areas, especially those undergoing rapid change in the specialty. Each issue, under the direction of the Editors and Guest Editors selected because of their expertise in the subject area, includes the most current information on the diagnosis and management of specific disorders of the skin, as well as the application of the latest scientific findings to patient care.
Seminars in Cutaneous Medicine and Surgery (ISSN 1085-5629) is published quarterly by Frontline Medical Communications Inc., 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609. Months of issue are March, June, September, and December. Periodicals postage paid at Parsippany, NJ, and additional mailing offices.
POSTMASTER: Send address changes to Seminars in Cutaneous Medicine and Surgery, Subscription Services, 110255 W Higgins Road, Suite 280, Rosemont, IL 60018.
RECIPIENT: To change your address, contact Subscription Services at 1-800-480-4851.
Editorial correspondence should be addressed to Kenneth A. Arndt, MD,
SkinCare Physicians of Chestnut Hill, 1244 Boylston St., Suite 302, Chestnut Hill, MA 02467. Correspondence regarding subscriptions or change of address should be directed to the Publisher, Subscription Services, 10255 W Higgins Road, Suite 280, Rosemont, IL 60018.
Subscriptions: Individual/Institution, USA: $133.00 p.a.; student, resident, intern, USA: $39.00. Individual, Canada/Mexico: $190.00 p.a.; institution, Canada/Mexico: $162.00 p.a. Individual, all other nations: $243.00 (surface mail), $311.00 (air mail); institution, all other nations: $188.
For back issues, call (800) 480-4851 to charge to your credit card. Written requests will be accepted and must be accompanied by check or money order. Send payment and request to Seminars in Cutaneous Medicine and Surgery, Subscription Service, 10255 W Higgins Road, Suite 280, Rosemont, IL 60018.
Copyright © 2018 by Frontline Medical Communications Inc. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission from the Publisher. Printed in the United States of America.
Licensing/Reprints/Eprints: Wright’s Media, 2407 Timberloch Place, Suite B, The Woodlands, TX 77386; Tel: 877-652-5295; Fax: 281-419-5712;
Email: [email protected].
Advertising representative: Sally Cioci, 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609. Phone: 973-290-8215; Fax: 973-206-9378; Email: [email protected].
Publication of an advertisement in Seminars in Cutaneous Medicine and Surgery does not imply endorsement of its claims by the Editor(s) or Publisher of the journal.
The ideas and opinions expressed in Seminars in Cutaneous Medicine and Surgery do not necessarily reflect those of the Editors or Publisher. Publication of an advertisement or other product mention in Seminars in Cutaneous Medicine and Surgery should not be construed as an endorsement of the product or the manufacturer’s claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. The Publisher does not assume any responsibility for any injury and/or damage to persons or property arising out of or related to any use of the material contained in this periodical. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications.
It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient.
Seminars in Cutaneous Medicine and Surgery is indexed in Index Medicus/MEDLINE.